Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 4/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.47 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787767 | 0.89 | MAPK1 (0.51) | AURKAAKR1C3AKR1C2MAPTPTK6 | |
| SCHEMBL7904950 | 0.82 | KDR (0.66) | MAPTCSNK2A1ALDH1A1LMNACYP1A2 | |
| SCHEMBL15052604 | 0.81 | RXRA (0.49) | AKR1C3AKR1C2PTGER4 | |
| SCHEMBL787562 | 0.76 | LMNA (0.56) | AURKAMAPTCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL15052797 | 0.76 | LMNA (0.56) | AURKAMAPTCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL15052803 | 0.76 | CSNK2A1 (0.63) | AURKAMAPTCSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL365112 | 0.75 | AKR1C3 (0.68) | AURKAAKR1C3AKR1C2MAPTMPO | |
| SCHEMBL23847681 | 0.73 | KDM4E (0.69) | AURKAAKR1C3AKR1C2MAPTCSNK2A1 | |
| SCHEMBL12697330 | 0.73 | MPO (0.67) | AKR1C3AKR1C2MAPTMPOTEAD4 | |
| SCHEMBL787904 | 0.73 | KDR (0.57) | MEN1ALDH1A1KMT2APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | claimed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | AURKA 341/4885AKR1C3 3184/4885AKR1C2 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.